Abstract
Ovarian cancer is the leading gynecologic malignancy with more than 22,000 new cases and 15,000 deaths estimated each year. It is usually detected in late stages with poor prognosis due to lack of sufficiently accurate screening tests. Epidemiological studies continue to support the notion that consumption of cruciferous vegetables reduces the risk of ovarian cancer. In the present review article, we describe the anti-cancer effects of 3, 3’-diindolylmethane (DIM), a compound present in cruciferous vegetables, against ovarian cancer. DIM targets multiple aspects of cancer such as cellcycle regulation and survival, including EGFR-JAK2-STAT3 signaling, checkpoint activation, caspase activation, endoplasmic reticulum stress, autophagy and anoikis. This broad spectrum of anti-cancer activities in conjunction with low systemic toxicity accentuates the translational value of DIM in cancer therapy. Together, our pre-clinical studies demonstrate that DIM has activity against ovarian cancer and hence should be further investigated in clinical setting to exploit its therapeutic potential.
Keywords: Diindolylmethane, cisplatin, STAT3, apoptosis, angiogenesis, anoikis, ER stress, autophagy, metastasis
Current Drug Targets
Title:DIMming Ovarian Cancer Growth
Volume: 13 Issue: 14
Author(s): Prabodh K. Kandala and Sanjay K. Srivastava
Affiliation:
Keywords: Diindolylmethane, cisplatin, STAT3, apoptosis, angiogenesis, anoikis, ER stress, autophagy, metastasis
Abstract: Ovarian cancer is the leading gynecologic malignancy with more than 22,000 new cases and 15,000 deaths estimated each year. It is usually detected in late stages with poor prognosis due to lack of sufficiently accurate screening tests. Epidemiological studies continue to support the notion that consumption of cruciferous vegetables reduces the risk of ovarian cancer. In the present review article, we describe the anti-cancer effects of 3, 3’-diindolylmethane (DIM), a compound present in cruciferous vegetables, against ovarian cancer. DIM targets multiple aspects of cancer such as cellcycle regulation and survival, including EGFR-JAK2-STAT3 signaling, checkpoint activation, caspase activation, endoplasmic reticulum stress, autophagy and anoikis. This broad spectrum of anti-cancer activities in conjunction with low systemic toxicity accentuates the translational value of DIM in cancer therapy. Together, our pre-clinical studies demonstrate that DIM has activity against ovarian cancer and hence should be further investigated in clinical setting to exploit its therapeutic potential.
Export Options
About this article
Cite this article as:
K. Kandala Prabodh and K. Srivastava Sanjay, DIMming Ovarian Cancer Growth, Current Drug Targets 2012; 13 (14) . https://dx.doi.org/10.2174/138945012804545650
DOI https://dx.doi.org/10.2174/138945012804545650 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Current Status of Ethosomes and Elastic Liposomes in Dermal and Transdermal Drug Delivery
Current Pharmaceutical Design Role of Flavonoids in the Prevention of Gynecological Cancers: Epidemiological Clues
Current Women`s Health Reviews Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia via mir-491
Anti-Cancer Agents in Medicinal Chemistry Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in Cancer
Current Topics in Medicinal Chemistry Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Cytotoxicity of a Vanadyl(IV) Complex with a Multidentate Oxygen Donor in Osteoblast Cell Lines in Culture
Medicinal Chemistry Prospects of Primary Ovarian Insufficiency Patient-Specific Pluripotent Stem Cells for Disease Modeling and Clinical Impacts
Current Women`s Health Reviews New Insights into Redox-Modulated Cell Signaling
Current Pharmaceutical Design Control of the Bone Morphogenetic Protein 7 Gene in Developmental and Adult Life
Current Genomics Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Ovarian Toxicity of Environmental Toxicants
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthetic Lipoproteins as Carriers for Drug Delivery
Current Medicinal Chemistry